| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/03/2003 | CA2461186A1 Novel screening method using prokineticin receptor |
| 04/03/2003 | CA2461150A1 Amines with antialcoholic agents |
| 04/03/2003 | CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity |
| 04/03/2003 | CA2461136A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 04/03/2003 | CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics |
| 04/03/2003 | CA2461080A1 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole |
| 04/03/2003 | CA2460953A1 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | CA2460780A1 Autologous growth factor cocktail composition, method of production and use |
| 04/03/2003 | CA2460344A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 04/03/2003 | CA2460000A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 04/03/2003 | CA2459999A1 Antagonists_and agonists of igf-1 receptor |
| 04/03/2003 | CA2459943A1 Androstanes as androgen receptor modulators |
| 04/03/2003 | CA2459807A1 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| 04/03/2003 | CA2458279A1 Modulation of vitamin storage |
| 04/03/2003 | CA2456281A1 Pyrane derivatives as both ace- and nep- inhibitors |
| 04/03/2003 | CA2455989A1 Neuroprotective treatment methods using selective inos inhibitors |
| 04/03/2003 | CA2446904A1 Delivery of drug esters through an inhalation route |
| 04/02/2003 | WO2002030891A1 Aliphatic nitrogenous five-membered ring compounds |
| 04/02/2003 | EP1298348A1 Bush, group of bush, suspension cross-member, vehicle, method for mounting a bush and method for mounting a group of bushes |
| 04/02/2003 | EP1298125A1 Substituted benzimidazole compounds and their use for the treatment of cancer |
| 04/02/2003 | EP1297841A1 Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs |
| 04/02/2003 | EP1297834A1 Inhibitor for enzyme having two divalent metal ions as active centers |
| 04/02/2003 | EP1297152A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 04/02/2003 | EP1297137A2 Gp286 nucleic acids and polypeptides |
| 04/02/2003 | EP1297130A2 G-protein coupled receptors |
| 04/02/2003 | EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 04/02/2003 | EP1297128A2 G-protein coupled receptors |
| 04/02/2003 | EP1297120A2 Liver-specific gene expression cassettes, and methods of use |
| 04/02/2003 | EP1297119A2 Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current |
| 04/02/2003 | EP1297017A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 04/02/2003 | EP1297014A2 Transporters and ion channels |
| 04/02/2003 | EP1297012A2 Novel fibroblast growth factors and nucleic acids encoding same |
| 04/02/2003 | EP1297002A2 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 04/02/2003 | EP1296996A1 Purine derivatives |
| 04/02/2003 | EP1296995A2 3'-prodrugs of 2'-deoxy-beta-l-nucleosides |
| 04/02/2003 | EP1296990A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 04/02/2003 | EP1296986A1 5-aminoalkyl-pyrazolo 4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect |
| 04/02/2003 | EP1296982A1 1-(heteroaryl-phenyl)-condensed pyrazol derivatives as factor xa inhibitors |
| 04/02/2003 | EP1296981A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 04/02/2003 | EP1296978A2 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 04/02/2003 | EP1296977A1 Heteroaryl-phenyl substituted factor xa inhibitors |
| 04/02/2003 | EP1296975A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 04/02/2003 | EP1296974A2 2-cyanopyrrolidine derivatives and their use as medicaments |
| 04/02/2003 | EP1296972A1 Arylmethylamine derivatives for use as tryptase inhibitors |
| 04/02/2003 | EP1296971A2 2-fluorobenzenesulfonyl compounds for the treatment of inflammation |
| 04/02/2003 | EP1296967A1 Quinolinyl and benzothiazolyl ppar-gamma modulators |
| 04/02/2003 | EP1296959A1 Methods and compositions utilizing quinazolinones |
| 04/02/2003 | EP1296954A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 04/02/2003 | EP1296951A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 04/02/2003 | EP1296949A2 Piperidine amides as modulators of chemokine receptor activity |
| 04/02/2003 | EP1296948A2 Novel gamma crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same. |
| 04/02/2003 | EP1296947A1 $g(A) CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT |
| 04/02/2003 | EP1296945A1 Sulfonamide derivatives |
| 04/02/2003 | EP1296944A1 Sulfonamide derivatives |
| 04/02/2003 | EP1296943A1 Amino acid derivatives and their use as medicines |
| 04/02/2003 | EP1296942A1 Glucagon antagonists/inverse agonists |
| 04/02/2003 | EP1296940A1 Amidine derivatives as selective antagonists of nmda receptors |
| 04/02/2003 | EP1296938A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| 04/02/2003 | EP1296936A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 04/02/2003 | EP1296934A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| 04/02/2003 | EP1296931A2 Polyamine analogues as cytotoxic agents |
| 04/02/2003 | EP1296716A2 New formulation |
| 04/02/2003 | EP1296714A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 04/02/2003 | EP1296708A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 04/02/2003 | EP1296702A1 Neuroprotective peptides |
| 04/02/2003 | EP1296701A1 Use of grifola frondosa fungus extracts |
| 04/02/2003 | EP1296700A1 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 04/02/2003 | EP1296699A1 Therapeutic agents - iii |
| 04/02/2003 | EP1296698A1 Therapeutic agents - ii |
| 04/02/2003 | EP1296697A1 Therapeutic agents - i |
| 04/02/2003 | EP1296693A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 04/02/2003 | EP1296690A2 METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES |
| 04/02/2003 | EP1296688A2 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide, oxy amide or 8-hydroxy quinoline structure |
| 04/02/2003 | EP1296687A2 Treatment of male sexual dysfunction |
| 04/02/2003 | EP1296681A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 04/02/2003 | EP1296679A1 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 04/02/2003 | EP1296677A2 Solid valsartan pharmaceutical compositions |
| 04/02/2003 | EP1296674A2 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 04/02/2003 | EP1296656A2 Method for preparing a composition |
| 04/02/2003 | EP1296650A2 Methods and compositions for treating pain of the mucous membrane |
| 04/02/2003 | EP1296567A2 Diet which induces ketosis in a canine or feline |
| 04/02/2003 | EP1228069B1 Bicyclic and tricyclic heteroaromatic compounds |
| 04/02/2003 | EP1226143B1 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 04/02/2003 | EP1212312B1 Novel derivatives of flavones, xanthones and coumarins |
| 04/02/2003 | EP1208100B1 Selective antagonists of a2b adenosine receptors |
| 04/02/2003 | EP1135145B1 Isolated material having an anti-organotrophic effect |
| 04/02/2003 | EP1121108B1 Novel therapeutic use of compounds with beta-3-agonist activity |
| 04/02/2003 | EP1114051B1 INHIBITORS OF p38 |
| 04/02/2003 | EP1045863B1 Detoxication of active pharmaceutical substances using cyclodextrine oligomers |
| 04/02/2003 | EP1021456B1 Macrocyclic 13-membered ring derivatives of erythromycins a and b |
| 04/02/2003 | EP0993304B1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 04/02/2003 | EP0991643B1 Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase |
| 04/02/2003 | EP0986387B1 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER |
| 04/02/2003 | EP0951467B1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE |
| 04/02/2003 | EP0894089B9 Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| 04/02/2003 | EP0873295B1 Dimer-selective rxr modulators and methods for their use |
| 04/02/2003 | EP0871464B1 Bradykinin analogs as selective thrombin inhibitors |
| 04/02/2003 | EP0865445B1 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties |
| 04/02/2003 | EP0847281B1 Method for detecting or monitoring the effectiveness of treatment of t cell mediated diseases |
| 04/02/2003 | EP0770081B1 Heterocycle-condensed morphinoid derivatives |